| Ident. | Authors (with country if any) | Title |
|---|
| 000050 (2021) |
Isabel S. Hernandes [Brésil] ; Haroldo C. Da Silva [Brésil] ; Hélio F. Dos Santos [Brésil] ; Wagner B. De Almeida [Brésil] | Unveiling the Molecular Structure of Antimalarial Drugs Chloroquine and Hydroxychloroquine in Solution through Analysis of 1H NMR Chemical Shifts. |
| 000094 (2021) |
Subham Das [Inde] ; Anu Kunnath Ramachandran [Inde] ; Sumit Raosaheb Birangal [Inde] ; Saleem Akbar [Inde] ; Bahar Ahmed [Inde] ; Alex Joseph [Inde] | The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. |
| 000116 (2021) |
Sathishkumar Chidambaram [Inde] ; Mohamed A. El-Sheikh [Arabie saoudite] ; Ahmed H. Alfarhan [Arabie saoudite] ; Surendrakumar Radhakrishnan [Inde] ; Idhayadhulla Akbar [Inde] | Synthesis of novel coumarin analogues: Investigation of molecular docking interaction of SARS-CoV-2 proteins with natural and synthetic coumarin analogues and their pharmacokinetics studies. |
| 000125 (2021) |
Andy Sing Ong Tang ; Tze Shin Leong ; Lee Ping Chew ; Hock Hin Chua | Successful Non-surgical Treatment of an Acute Calculous Cholecystitis in a Myeloma Patient with Covid-19: Case Report. |
| 000127 (2021) |
Thirumal Kumar D [Inde] ; Nishaat Shaikh [Inde] ; Udhaya Kumar S [Inde] ; George Priya Doss C [Inde] ; Hatem Zayed [Qatar] | Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2. |
| 000128 (2021) |
Deepak Mishra [Inde] ; Radha Raman Maurya [Inde] ; Kamlesh Kumar [Inde] ; Nupur S. Munjal [Inde] ; Vijay Bahadur [Inde] ; Sandeep Sharma [Inde] ; Prashant Singh [Inde] ; Indra Bahadur [Afrique du Sud] | Structurally modified compounds of hydroxychloroquine, remdesivir and tetrahydrocannabinol against main protease of SARS-CoV-2, a possible hope for COVID-19: Docking and molecular dynamics simulation studies. |
| 000129 (2021) |
Sinosh Skariyachan [Inde] ; Dharshini Gopal [Inde] ; Aditi G. Muddebihalkar [Inde] ; Akshay Uttarkar [Inde] ; Vidya Niranjan [Inde] | Structural insights on the interaction potential of natural leads against major protein targets of SARS-CoV-2: Molecular modelling, docking and dynamic simulation studies. |
| 000130 (2021) |
Yudibeth Sixto-L Pez [Mexique] ; José Correa-Basurto [Mexique] ; Martiniano Bello [Mexique] ; Bruno Landeros-Rivera [France] ; Jose Antonio Garz N-Tiznado [Mexique] ; Sarita Monta O [Mexique] | Structural insights into SARS-CoV-2 spike protein and its natural mutants found in Mexican population. |
| 000133 (2021) |
Isidro García-Meni O [Espagne] ; Lorena Forcelledo [Espagne] ; Yaiza Rosete [Espagne] ; Emilio García-Prieto [Espagne] ; Dolores Escudero [Espagne] ; Javier Fernández [Espagne] | Spread of OXA-48-producing Klebsiella pneumoniae among COVID-19-infected patients: The storm after the storm. |
| 000174 (2021) |
Abdo A. Elfiky [Égypte] | SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective. |
| 000203 (2021) |
F O Shode [Afrique du Sud] ; A S K. Idowu [Afrique du Sud] ; O J Uhomoibhi [Afrique du Sud] ; S. Sabiu [Afrique du Sud] | Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2. |
| 000233 (2021) |
Olfa Noureddine [Tunisie] ; Noureddine Issaoui [Tunisie] ; Mouna Medimagh [Tunisie] ; Omar Al-Dossary [Arabie saoudite] ; Houda Marouani [Tunisie] | Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: Molecular docking and DFT calculations. |
| 000264 (2021) |
Yanqiang Han ; Zhilong Wang ; Jiahao Ren ; Zhiyun Wei ; Jinjin Li [République populaire de Chine] | Potential inhibitors for the novel coronavirus (SARS-CoV-2). |
| 000271 (2021) |
Ahmed A. Ishola [Nigeria] ; Kayode E. Adewole [Nigeria] ; Habibu Tijjani [Nigeria] ; Suliat I. Abdulai [Nigeria] ; Nnaemeka T. Asogwa [Nigeria] | Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs. |
| 000295 (2021) |
Zheng Zequn [République populaire de Chine] ; Wu Yujia [République populaire de Chine] ; Qian Dingding [République populaire de Chine] ; Lian Jiangfang [République populaire de Chine] | Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. |
| 000307 (2021) |
Shweta A. More [Inde] ; Akshay S. Patil [États-Unis] ; Nikhil S. Sakle [Inde] ; Santosh N. Mokale [Inde] | Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs. |
| 000315 (2021) |
Cristina Ciuca [Italie] ; Marianna Fabi [Italie] ; Daniela Di Luca [Italie] ; Fabio Niro [Italie] ; Chiara Ghizzi [Italie] ; Andrea Donti [Italie] ; Anna Balducci [Italie] ; Alessandro Rocca [Italie] ; Chiara Zarbo [Italie] ; Gaetano Domenico Gargiulo [Italie] ; Marcello Lanari [Italie] | Myocarditis and coronary aneurysms in a child with acute respiratory syndrome coronavirus 2. |
| 000326 (2021) |
C N Prashantha [Inde] ; K. Gouthami [Inde] ; L. Lavanya [Inde] ; Sivaramireddy Bhavanam [Inde] ; Ajay Jakhar [Inde] ; R G Shakthiraju [Inde] ; V. Suraj [Inde] ; K V Sahana [Inde] ; H S Sujana [Inde] ; N M Guruprasad [Inde] ; R. Ramachandra [Inde] | Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. |
| 000327 (2021) |
Yashwant Kumar Ratre [Inde] ; Namrata Kahar [Inde] ; L V K S. Bhaskar [Inde] ; Antaripa Bhattacharya [Italie] ; Henu Kumar Verma [Italie] | Molecular mechanism, diagnosis, and potential treatment for novel coronavirus (COVID-19): a current literature review and perspective. |
| 000328 (2021) |
R. Thirumalaisamy [Inde] ; V. Aroulmoji [Inde] ; Muhammad Nasir Iqbal [Pakistan] ; M. Deepa [Inde] ; C. Sivasankar [Inde] ; Riaz Khan [Royaume-Uni] ; T. Selvankumar [Inde] | Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins. |
| 000329 (2021) |
Netra Prasad Neupane [Inde] ; Abhishek Kumar Karn [Inde] ; Imdad Husen Mukeri [Inde] ; Prateek Pathak [Russie] ; Praveen Kumar [Inde] ; Samayaditya Singh [Inde] ; Insaf Ahmed Qureshi [Inde] ; Tarun Jha [Inde] ; Amita Verma [Inde] | Molecular dynamics analysis of phytochemicals from Ageratina adenophora against COVID-19 main protease (Mpro) and human angiotensin-converting enzyme 2 (ACE2). |
